ArticleGenes2014
Pharmacogenomics: Current State-of-the-Art.
Article in Genes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- The Intersection between Pharmacogenomics and Health Equity: A Case Example.Pharmacy (Basel, Switzerland) · 2023Review
- LCMD: Lung Cancer Metabolome Database.Computational and structural biotechnology journal · 2022Article
- The Person's Care Requires a Sex and Gender Approach.Journal of clinical medicine · 2021Review
- Just a Reflection: Does Drug Repurposing Perpetuate Sex-Gender Bias in the Safety Profile?Pharmaceuticals (Basel, Switzerland) · 2021Review
- Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations.Pharmaceutics · 2020Article
- Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms.The pharmacogenomics journal · 2019Article
- Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records.European journal of human genetics : EJHG · 2019Article
- Advancing Personalized Medicine Through the Application of Whole Exome Sequencing and Big Data Analytics.Frontiers in genetics · 2019Review
- Microfluidic approaches for cell-based molecular diagnosis.Biomicrofluidics · 2018Article
- A review of metabolism-associated biomarkers in lung cancer diagnosis and treatment.Metabolomics : Official journal of the Metabolomic Society · 2018Article
- State of Art of Cancer Pharmacogenomics in Latin American Populations.International journal of molecular sciences · 2017Review
- Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy.Metabolomics : Official journal of the Metabolomic Society · 2017Article
- Companion diagnostics-a tool to improve pharmacotherapy.Annals of translational medicine · 2016Review
- The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity.International journal of molecular sciences · 2016Review
- Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery.Nature reviews. Endocrinology · 2016Review
- Mismatch detection in DNA monolayers by atomic force microscopy and electrochemical impedance spectroscopy.Beilstein journal of nanotechnology · 2016Article
- Advances in the Pharmacogenomics of Adverse Drug Reactions.Drug safety · 2016Review
- Pharmacogenomics in the clinic.Nature · 2015Review
- Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors.Seminars in oncology · 2015Review
- Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.International journal of molecular sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The completion of the human genome project 10 years ago was met with great optimism for improving drug therapy through personalized medicine approaches, with the anticipation that an era of genotype-guided patient prescribing was imminent. To some extent this has come to pass and a number of key pharmacogenomics markers of inter-individual drug response, for both safety and efficacy, have been identified and subsequently been adopted in clinical practice as pre-treatment genetic tests. However, the universal application of genetics in treatment guidance is still a long way off. This review will highlight important pharmacogenomic discoveries which have been facilitated by the human genome project and other milestone projects such as the International HapMap and 1000 genomes, and by the continued development of genotyping and sequencing technologies, including rapid point of care pre-treatment genetic testing. However, there are still many challenges to implementation for the many other reported biomarkers which continue to languish within the discovery phase. As technology advances over the next 10 years, and the costs fall, the field will see larger genetic data sets, including affordable whole genome sequences, which will, it is hoped, improve patient outcomes through better diagnostic, prognostic and predictive biomarkers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.